Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 1/20 | 0.73 |
| ▸ | HPGDS | O60760 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22939414 | 1.00 | MLLT1 (0.73) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL22939368 | 0.88 | MLLT1 (0.56) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL25480030 | 0.83 | MLLT1 (0.88) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL25513463 | 0.82 | MLLT1 (0.87) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL25483890 | 0.81 | MLLT1 (0.84) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL31460463 | 0.74 | HPGDS (0.64) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL22939439 | 0.73 | MLLT1 (0.61) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL22939441 | 0.73 | MAPT (0.64) | MLLT1HPGDSKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL25481028 | 0.72 | MLLT1 (0.66) | MLLT1HPGDS | |
| SCHEMBL25481018 | 0.72 | MLLT1 (0.63) | MLLT1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274980-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274980-A1 | PHARMACOLOGICAL INHIBITORS OF THE ENL YEATS DOMAIN | YEATS2, MLLT1, YEATS4 | MLLT1 2/4885HPGDS 1134/4885KDM4E 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.